CYP2E1 and metabolic dysfunction-associated steatotic liver disease: Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD) [18], is also associated with increased CYP2E1 activity and is accompanied by an increased risk of APAP-induced hepatotoxicity [19].